Last reviewed · How we verify
Dasatinib, Paclitaxel, and Carboplatin — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Dasatinib, Paclitaxel, and Carboplatin (Dasatinib, Paclitaxel, and Carboplatin) — AA Secord.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Dasatinib, Paclitaxel, and Carboplatin TARGET | Dasatinib, Paclitaxel, and Carboplatin | AA Secord | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Dasatinib, Paclitaxel, and Carboplatin CI watch — RSS
- Dasatinib, Paclitaxel, and Carboplatin CI watch — Atom
- Dasatinib, Paclitaxel, and Carboplatin CI watch — JSON
- Dasatinib, Paclitaxel, and Carboplatin alone — RSS
Cite this brief
Drug Landscape (2026). Dasatinib, Paclitaxel, and Carboplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/dasatinib-paclitaxel-and-carboplatin. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab